Oxaliplatin-induced neuropathy in colorectal cancer: Many questions with few answers

Clinical Colorectal Cancer

Volumn 13, Issue 2, 2014, Pages 73-80

  Zedan, Ahmed Hussein ^a   Hansen, Torben Frøstrup ^a   Svenningsen, Åsa Fex ^b   Vilholm, Ole Jakob ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Colon cancer; Neuropathy; Oxaliplatin

Indexed keywords

ACETYLCYSTEINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLUTATHIONE; IRINOTECAN; OXALIPLATIN; RALTITREXED; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

CLINICAL FEATURE; COLORECTAL CANCER; DRUG TARGETING; HUMAN; NEUROPATHY; NEUROTOXICITY; OTOTOXICITY; OXALIPLATIN INDUCED POLYNEUROPATHY; POLYNEUROPATHY; QUALITY OF LIFE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPINAL GANGLION; ACUTE DISEASE; ANIMAL; CHEMICALLY INDUCED; CHRONIC DISEASE; COLORECTAL NEOPLASMS; NEUROTOXICITY SYNDROMES; PATHOPHYSIOLOGY; PHARMACOGENETICS;

ACUTE DISEASE; ANIMALS; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; COLORECTAL NEOPLASMS; HUMANS; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; PHARMACOGENETICS; POLYNEUROPATHIES;

EID: 84900472865     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2013.11.004     Document Type: Review

References (109)

1. A. De Gramont, A. Figer, and M. Seymour et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947
2. T. André, C. Boni, and L. Mounedji-Boudiaf et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 350 2004 2343 2351
3. E.S. O'Connor, D.Y. Greenblatt, and N.K. LoConte et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features J Clin Oncol 29 2011 3381 3388
4. E. Raymond, S. Faivre, and J.M. Woynarowski et al. Oxaliplatin: mechanism of action and antineoplastic activity Semin Oncol 25 1998 4 12
5. E. Gamelin, L. Gamelin, and L. Bossi et al. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures Semin Oncol 29 2002 21 33
6. A. Grothey Oxaliplatin-safety profile: neurotoxicity Semin Oncol 30 2003 5 13
7. A. Grothey Clinical management of oxaliplatin-associated neurotoxicity Clin Colorectal Cancer 5 suppl1 2005 S38 S46
8. J. Graham, M. Mushin, and P. Kirkpatrick Oxaliplatin Nat Rev Drug Discov 3 2004 11 12
9. S.R. Land, J.A. Kopec, and R.S. Cecchini et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07 J Clin Oncol 25 2007 2205 2211
10. J.M. Extra, M. Espie, and F. Calvo et al. Phase I study of oxaliplatin in patients with advanced cancer Cancer Chemother Pharmacol 25 1990 299 303
11. J.M. Extra, M. Marty, and S. Brienza et al. Pharmacokinetics and safety profile of oxaliplatin Semin Oncol 25 1998 13 22
12. A. Grothey, and R.M. Goldberg A review of oxaliplatin and its clinical use in colorectal cancer Expert Opin Pharmacother 5 2004 2159 2170
13. M.W. Saif, and J. Reardon Management of oxaliplatin-induced peripheral neuropathy Ther Clin Risk Manag 1 2005 249 258
14. S.B. Park, M. Koltzenburg, and C.S.Y. Lin et al. Longitudinal assessment of oxaliplatin-induced neuropathy Neurology 78 2012 152
15. A.V. Krishnan, D. Goldstein, and M. Friedlander et al. Oxaliplatin-induced neurotoxicity and the development of neuropathy Muscle Nerve 32 2005 51 60
16. L. Gamelin, M. Boisdron-Celle, and R. Delva et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer Clin Cancer Res 10 2004 4055 4061
17. L. Gamelin, O. Capitain, and A. Morel et al. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway Clin Cancer Res 13 2007 6359 6368
18. S.B. Park, C.S.Y. Lin, and A.V. Krishnan et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy Brain 132 2009 2712 2723
19. S. Taieb, V. Trillet-Lenoir, and L. Rambaud et al. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients Cancer 94 2002 2434 2440
20. R.H. Wilson, T. Lehky, and R.R. Thomas et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability J Clin Oncol 20 2002 1767 1774
21. + channel function in vivo Clin Cancer Res 12 2006 4481 4484
22. S.B. Park, D. Goldstein, and C.S.Y. Lin et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity J Clin Oncol 27 2009 1243 1249
23. S.B.S. Park, C.S.Y. Lin, and M.M.C. Kiernan Nerve excitability assessment in chemotherapy-induced neurotoxicity J Vis Exp 62 2012 1 5
24. G. Lauria, S.T. Hsieh, and O. Johansson et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society Eur J Neurol 17 2010 903 912
25. N. Attal, D. Bouhassira, and M. Gautron et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study Pain 144 2009 245 252
26. + channel kinetics on rat sensory neurons Eur J Pharmacol 406 2000 25 32
27. R.G. Webster, K.L. Brain, and R.H. Wilson et al. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels Br J Pharmacol 146 2005 1027 1039
28. A. Kagiava, A. Tsingotjidou, and C. Emmanouilides et al. The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat Neurotoxicology 29 2008 1100 1106
29. L.J. Ptácek, A.L. George, and R.L. Barchi et al. Mutations in an S4 segment of the adult skeletal muscle sodium channel cause paramyotonia congenita Neuron 8 1992 891 897
30. E.K. Wittmack, A.M. Rush, and M.J. Craner et al. Fibroblast growth factor homologous factor 2B: association with Nav1.6 and selective colocalization at nodes of Ranvier of dorsal root axons J Neurosci 24 2004 6765 6775
31. R. Sittl, A. Lampert, and T. Huth et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current Proc Natl Acad Sci U S A 109 2012 6704 6709
32. E.K. Joseph, X. Chen, and O. Bogen et al. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy J Pain 9 2008 463 472
33. A.G. Dimitrov, and N.A. Dimitrova A possible link of oxaliplatin-induced neuropathy with potassium channel deficit Muscle Nerve 45 2012 403 411
34. I. Mogyoros, H. Bostock, and D. Burke Mechanisms of paresthesias arising from healthy axons Muscle Nerve 23 2000 310 320
35. F. Grolleau, L. Gamelin, and M. Boisdron-Celle et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels J Neurophysiol 85 2001 2293 2297
36. T. Alcindor, and N. Beauger Oxaliplatin: a review in the era of molecularly targeted therapy Curr Oncol 18 2011 18 25
37. V. Bockhart, C.E. Constantin, and A. Häussler et al. Inhibitor kappaB kinase beta deficiency in primary nociceptive neurons increases TRP channel sensitivity J Neurosci 29 2009 12919 12929
38. M. Bandell, G.M. Story, and S.W. Hwang et al. Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin Neuron 41 2004 849 857
39. C.R. McNamara, J. Mandel-Brehm, and D.M. Bautista et al. TRPA1 mediates formalin-induced pain Proc Natl Acad Sci U S A 104 2007 13525 13530
40. G.M. Story, A.M. Peier, and A.J. Reeve et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures Cell 112 2003 819 829
41. N. Takahashi, Y. Mizuno, and D. Kozai et al. Molecular characterization of TRPA1 channel activation by cysteine-reactive inflammatory mediators Channels 2 2008 287 298
42. A. Verkhratsky, and C. Steinhäuser Ion channels in glial cells Brain Res Brain Res Rev 32 2000 380 412
43. J. Scholz, and C.J. Woolf The neuropathic pain triad: neurons, immune cells and glia Nat Neurosci 10 2007 1361 1368
44. R.A. Warwick, and M. Hanani The contribution of satellite glial cells to chemotherapy-induced neuropathic pain Eur J Pain 17 2012 1 10
45. L. Bonaccini, and T. Mello Oxaliplatin-induced neuropathy: glial activation in spinal cord and brain Ital J Anat Embryol 115 2010
46. G. Cavaletti, G. Tredici, and M.G. Petruccioli et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat Eur J Cancer 37 2001 2457 2463
47. A.A. Argyriou, P. Polychronopoulos, and G. Iconomou et al. A review on oxaliplatin-induced peripheral nerve damage Cancer Treat Rev 34 2008 368 377
48. J.S. Gill, and A.J. Windebank Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle J Clin Invest 101 1998 2842 2850
49. A. Scuteri, A. Galimberti, and D. Maggioni et al. Role of MAPKs in platinum-induced neuronal apoptosis Neurotoxicology 30 2009 312 319
50. W.P. Yong, F. Innocenti, and M.J. Ratain The role of pharmacogenetics in cancer therapeutics Br J Clin Pharmacol 62 2006 35 46
51. G. Cavaletti, P. Alberti, and P. Marmiroli Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics Lancet Oncol 12 2011 1151 1161
52. D.M. Kweekel, H. Gelderblom, and H.J. Guchelaar Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy Cancer Treat Rev 31 2005 90 105
53. M.A. Watson, R.K. Stewart, and G.B. Smith et al. Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution Carcinogenesis 19 1998 275 280
54. B. Ketterer, J.M. Harris, and G. Talaska et al. The human glutathione S-transferase supergene family, its polymorphism, and its effects on susceptibility to lung cancer Environ Health Perspect 98 1992 87 94
55. F. Ali-Osman, O. Akande, and G. Antoun et al. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase pi gene variants: evidence for differential catalytic activity of the encoded proteins J Biol Chem 272 1997 10004 10012
56. A.C. Blackburn, E. Woollatt, and G.R. Sutherland et al. Characterization and chromosome location of the gene GSTZ1 encoding the human zeta class glutathione transferase and maleylacetoacetate isomerase Cytogenet Genome Res 83 1998 109 114
57. J.A. Moscow, C.R. Fairchild, and M.J. Madden et al. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors Cancer Res 49 1989 1422 1428
58. A. Hirvonen Polymorphisms of xenobiotic-metabolizing enzymes and susceptibility to cancer Environ Health Perspect 107 suppl 1999 37 47
59. J. Stoehlmacher, D.J. Park, and W. Zhang et al. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer J Natl Cancer Inst 94 2002 936 942
60. J. Stoehlmacher, D.J. Park, and W. Zhang et al. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer Br J Cancer 91 2004 344 354
61. T. Lecomte, B. Landi, and P. Beaune et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy Clin Cancer Res 12 2006 3050 3056
62. L. Pare, E. Marcuello, and A. Altes et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy Br J Cancer 99 2008 1050 1055
63. E. Goekkurt, S.E. Al-Batran, and J.T. Hartmann et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie J Clin Oncol 27 2009 2863 2873
64. J. Hong, S.-W. Han, and H.S. Ham et al. Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis Cancer Chemother Pharmacol 67 2011 1323 1331
65. M. Inada, M. Sato, and S. Morita et al. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes Int J Clin Pharmacol Ther 48 2010 729 734
66. Y.C. Chen, C.H. Tzeng, and P.M. Chen et al. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma Cancer Sci 101 2010 530 535
67. B. Van Houten Nucleotide excision repair in Escherichia coli Microbiol Rev 54 1990 18 51
68. V. Boige, J. Mendiboure, and J.P. Pignon et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05 J Clin Oncol 28 2010 2556 2564
69. D.M. Kweekel, H. Gelderblom, and N.F. Antonini et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients Eur J Cancer 45 2009 572 578
70. B. Keam, S.A. Im, and S.W. Han et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker BMC Cancer 8 2008 148
71. B.G. Seo, H.C. Kwon, and S.Y. Oh et al. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI Oncol Rep 22 2009 127 136
72. R. Zarate, J. Rodriguez, and E. Bandres et al. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis Br J Cancer 102 2010 987 994
73. M. Kanai, A. Yoshioka, and S. Tanaka et al. Associations between glutathione S-transferase π Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy Cancer Epidemiol 34 2010 189 193
74. A. Ruzzo, F. Graziano, and K. Kawakami et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy J Clin Oncol 25 2007 1247 1254
75. A. Grothey, H.L. McLeod, and E.M. Green et al. Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity J Clin Oncol 23 2005 3509
76. F. Levi, B. Perpoint, and C. Garufi et al. Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate Eur J Cancer 29A 1993 1280 1284
77. A.G. Antonacopoulou, A.A. Argyriou, and C.D. Scopa et al. Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? Eur J Neurol 17 2010 963 968
78. N. Knijn, J. Tol, and M. Koopman et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients Eur J Cancer 47 2011 369 374
79. H.S. Hochster, A. Grothey, and B.H. Childs Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity J Clin Oncol 25 2007 4028 4029
80. A. Grothey, D.A. Nikcevich, and J.A. Sloan et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7 J Clin Oncol 29 2011 421 427
81. L. Gamelin, M. Boisdron-Celle, and A. Morel et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy J Clin Oncol 26 2008 1188 1189 author reply 1189-90
82. G. Cavaletti, and M.A. Khattak Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity? The Oncologist 16 2011 1667 1668
83. G. Cavaletti, and P. Marmiroli The role of growth factors in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity Curr Drug Saf 1 2006 35 42
84. E.M. Park, J.H. Choi, and J.S. Park et al. Measurement of glutathione oxidation and 8-hydroxy-2′-deoxyguanosine accumulation in the gerbil hippocampus following global ischemia Brain Res Brain Res Protoc 6 2000 25 32
85. A.A. Argyriou, P. Polychronopoulos, and E. Chroni The usefulness of nerve conduction studies in objectively assessing oxaliplatin-induced peripheral neuropathy The Oncologist 12 2007 1371 1372 author reply 1372-1373
86. S. Cascinu, V. Catalano, and L. Cordella et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial J Clin Oncol 20 2002 3478 3483
87. P. Milla, M. Airoldi, and G. Weber et al. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity Anticancer Drugs 20 2009 396 402
88. P.C. Lin, M.Y. Lee, and W.S. Wang et al. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data Support Care Cancer 14 2006 484 487
89. O. Ghirardi, P. Lo Giudice, and C. Pisano et al. Acetyl-l-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties Anticancer Res 25 2005 2681 2687
90. A.J. Ocean, and L.T. Vahdat Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies Support Care Cancer 12 2004 619 625
91. S. Wolf, D. Barton, and L. Kottschade et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies Eur J Cancer 44 2008 1507 1515
92. W.S. Wang, J.K. Lin, and T.C. Lin et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients The Oncologist 12 2007 312 319
93. L. Vahdat, K. Papadopoulos, and D. Lange et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine Clin Cancer Res 7 2001 1192 1197
94. V.S. Klimberg, and J.L. McClellan Claude H. Organ, Jr. Honorary Lectureship: glutamine, cancer, and its therapy Am J Surg 172 1996 418 424
95. R.J. Smith, and D.W. Wilmore Glutamine nutrition and requirements J Parenter Enteral Nutr 14 1990 94S 99S
96. F. Marchand, A. Alloui, and T. Pelissier et al. Evidence for an antihyperalgesic effect of venlafaxine in vincristine-induced neuropathy in rat Brain Res 980 2003 117 120
97. J.P. Durand, C. Brezault, and F. Goldwasser Protection against oxaliplatin acute neurosensory toxicity by venlafaxine Anticancer Drugs 14 2003 423 425
98. T.J. Kaley, and L.M. Deangelis Therapy of chemotherapy-induced peripheral neuropathy Br J Haematol 145 2009 3 14
99. J.P. Durand, G. Deplanque, and V. Montheil et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial Ann Oncol 23 2012 200 205
100. S. Von Delius, F. Eckel, and S. Wagenpfeil et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study Invest New Drugs 25 2007 173 180
101. A.A. Argyriou, E. Chroni, and P. Polychronopoulos et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy Neurology 67 2006 2253 2255
102. J.W.J. Albers, V. Chaudhry, and G. Cavaletti et al. Interventions for preventing neuropathy caused by cisplatin and related compounds Cochrane Database Syst Rev 2011 CD005228
103. G. Cavaletti, P. Alberti, and B. Frigeni et al. Chemotherapy-induced neuropathy Curr Treat Options Neurol 13 2011 180 190
104. T.S. Jensen, R. Baron, and M. Haanpää et al. A new definition of neuropathic pain Pain 152 2011 2204 2205
105. N.B. Finnerup, S.H. Sindrup, and T.S. Jensen The evidence for pharmacological treatment of neuropathic pain Pain 150 2010 573 581
106. N. Attal, G. Cruccu, and R. Baron et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision Eur J Neurol 17 2010 1113-e88
107. H. Sada, N. Egashira, and S. Ushio et al. Repeated administration of amitriptyline reduces oxaliplatin-induced mechanical allodynia in rats J Pharmacol Sci 118 2012 547 551
108. N. Egashira, S. Hirakawa, and T. Kawashiri et al. Mexiletine reverses oxaliplatin-induced neuropathic pain in rats J Pharmacol Sci 112 2010 473 476
109. S. Ushio, N. Egashira, and H. Sada et al. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting anti-tumour efficacy in rodents Eur J Cancer 48 2012 1407 1413